LivaNova PLC (LIVN) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$70.92
Price Target
$75.88
Target Range
$66.00 — $85.00
Analyst Rating
Buy
Forward P/E16.8x
Trailing P/E-15.9x
Forward PEG—
Implied Growth+119.7%
Median Target$77.50
Analyst Spread25.0%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$66
-6.9%
Consensus
$76
+7.0%
Bull Case
$85
+19.8%
LIVN Price Target Analysis
Updated May 8, 2026As of May 8, 2026, LivaNova PLC (LIVN) has a Wall Street consensus price target of $75.88, based on estimates from 14 covering analysts. With the stock currently trading at $70.92, this represents a potential upside of +7.0%. The company has a market capitalization of $3.88B.
Analyst price targets range from a low of $66.00 to a high of $85.00, representing a 25% spread in expectations. The median target of $77.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 10 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, LIVN trades at a trailing P/E of -15.9x and forward P/E of 16.8x. Analysts expect EPS to grow +119.7% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+44.3%
Avg Forward P/E20.5x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NVCRNovoCure Limited | $1.9B | $16.83 | $33.50 | +99.0% | Buy | — | 15 |
 INVAInnoviva, Inc. | $1.9B | $22.80 | $37.67 | +65.2% | Buy | 11.9x | 10 |
 GKOSGlaukos Corporation | $7.9B | $134.15 | $146.67 | +9.3% | Buy | — | 24 |
 MDTMedtronic plc | $99.9B | $77.96 | $109.50 | +40.5% | Buy | 14.1x | 49 |
 ABTAbbott Laboratories | $151.3B | $87.01 | $128.71 | +47.9% | Buy | 15.9x | 41 |
 BSXBoston Scientific Corporation | $84.1B | $56.58 | $91.33 | +61.4% | Buy | 16.7x | 43 |
 SYKStryker Corporation | $112.7B | $294.25 | $403.69 | +37.2% | Buy | 19.6x | 50 |
 ELMDElectromed, Inc. | $222M | $26.86 | $38.00 | +41.5% | Buy | 24.4x | 4 |
 HOLXHologic, Inc. | $17.0B | $76.01 | $79.00 | +3.9% | Hold | 17.2x | 42 |
 ISRGIntuitive Surgical, Inc. | $161.1B | $453.49 | $622.60 | +37.3% | Buy | 43.8x | 55 |
Upside Potential Comparison
NVCRINVABSXABTELMDMDTISRGSYKSee LIVN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LIVN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LIVN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLIVN — Frequently Asked Questions
Quick answers to the most common questions about buying LIVN stock.
What is the LIVN stock price target for 2026?
The consensus price target for LIVN is $75.88, close to the current price of $70.925 (7.0% implied move). Based on 14 analyst estimates, the stock appears fairly valued near current levels.
Is LIVN a buy, sell, or hold?
LIVN has a consensus rating of "Buy" based on 14 Wall Street analysts. The rating breakdown is predominantly bullish, with 10 Buy/Strong Buy ratings. The consensus 12-month price target of $75.88 implies 7.0% upside from current levels.
Is LIVN stock overvalued or undervalued?
With a forward P/E of 16.8448x, LIVN trades at a relatively low valuation. The consensus target of $75.88 implies 7.0% appreciation, suggesting the market may be pricing in risks.
How high can LIVN stock go?
The most bullish Wall Street analyst has a price target of $85 for LIVN, while the most conservative target is $66. The consensus of $75.88 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover LIVN stock?
LIVN is moderately covered, with 14 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 10 have Buy ratings, 3 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the LIVN stock forecast?
The 12-month LIVN stock forecast based on 14 Wall Street analysts shows a consensus price target of $75.88, with estimates ranging from $66 (bear case) to $85 (bull case). The median consensus rating is "Buy".
What is LIVN's forward P/E ratio?
LIVN trades at a forward P/E ratio of 16.8x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy LIVN stock?
LIVN appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $75.88 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do LIVN price targets vary so much?
LIVN analyst price targets range from $66 to $85, a 25% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $75.88 consensus represents the middle ground.